Lung cancer immunotherapy.

Luis E. Raez, Steven Fein, Eckhard R. Podack

Research output: Contribution to journalReview article

49 Scopus citations

Abstract

Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies, some of which generate active immune responses against tumor-associated antigens. Understanding the mechanisms of anti-tumor immunity and identifying target antigens will likely improve these therapeutic strategies and provide them with a niche in the future of lung cancer therapy.

Original languageEnglish (US)
Pages (from-to)221-228
Number of pages8
JournalClinical medicine & research
Volume3
Issue number4
DOIs
StatePublished - Nov 2005

    Fingerprint

ASJC Scopus subject areas

  • Community and Home Care

Cite this

Raez, L. E., Fein, S., & Podack, E. R. (2005). Lung cancer immunotherapy. Clinical medicine & research, 3(4), 221-228. https://doi.org/10.3121/cmr.3.4.221